| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $19.9M | +236.9% |
| R&D Expense | $61.3M | -34.5% |
| SG&A Expense | $37.8M | -25.7% |
| Operating Income | -$142.4M | -2.8% |
| Income Tax | $0 | — |
| Net Income | -$131.7M | -4.0% |
| EPS (Basic) | -$1.98 | -1.0% |
| EPS (Diluted) | -$1.98 | -1.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $76.3M | +14.8% |
| Short-term Investments | $108.9M | -45.0% |
| Accounts Receivable | $1.2M | — |
| Current Assets | $192.9M | -29.2% |
| Total Assets | $231.2M | -38.3% |
| Current Liabilities | $35.1M | -12.2% |
| Total Liabilities | $145.0M | -15.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$88.6M | -67.9% |
| Capital Expenditures | $2.4M | -67.5% |
| Investing Cash Flow | $94.5M | +1074.7% |
| Financing Cash Flow | $250K | -99.3% |
| Free Cash Flow | -$91.0M | -51.2% |
| Stockholders' Equity |
| $86.2M |
| -57.6% |